Navigation Links
NAMSA opens Shanghai office
Date:9/20/2012

NORTHWOOD, Ohio, Sept. 20, 2012 /PRNewswire/ -- NAMSA, the world's leading medical device research organization, has opened its newest office in Shanghai, China.

(Photo: http://photos.prnewswire.com/prnh/20120920/CL78591 )

The new office will provide improved convenience and efficiency for NAMSA's clients in China and around the world. The Shanghai office allows NAMSA to better support Chinese manufacturers in meeting European and U.S. regulatory requirements. Additionally, the company is better positioned to assist device manufacturers outside China to meet the necessary standards for marketing products in China.

"This expansion benefits all of NAMSA's current and potential clients," said An Liu, general manager, NAMSA China. "Chinese manufacturers can trust in our proven ability to successfully support meeting European and U.S. regulatory requirements, while those manufacturers outside China aiming to distribute products within China can rely on our expertise and proximity for convenient assistance in meeting the country's regulatory demands."

In his new role, Liu is responsible for establishing and developing NAMSA China business. He previously served as director of biostatistics and data management for NAMSA. Before joining NAMSA, Liu served as statistics manager for Medtronic.

"NAMSA is pleased to be in a position to expand and better serve our partners with world-class expertise in regulatory, non-clinical and clinical research services," said Terence Langenderfer, Director of Global Marketing, NAMSA. "It has always been our intention to provide the best strategic guidance and tactical support in the most cost-effective and seamless manner. This expansion in China supports that mission."

To coincide with the opening of the Shanghai office, NAMSA will be presenting at MEDTEC China – the international regulatory conference for the medical device manufacturing industry – on Sept. 26. In addition to Liu, who will present on "Cardiovascular Devices: US FDA Regulatory Requirement and Clinical Trial Design", Dr. Jean Pierre Boutrand, general manager of NAMSA in Lyon, France, and one of NAMSA's top biocompatibility experts, will present on European regulations.

These presenters will be available to meet with participants at MEDTEC China exhibit hall; booth 1501.

About NAMSA
NAMSA (www.namsa.com) is a global medical device research organization providing a comprehensive range of services to prove efficacy, non-clinical and clinical safety of medical devices, IVDs and combination products. For more than 45 years, NAMSA clients have utilized its testing and consulting services to bring safe and effective therapies to market.

Contact Information
For further information about NAMSA, contact:
Sean Hamilton
Marketing Communications Manager
419.662.4846
shamilton@namsa.com


'/>"/>
SOURCE NAMSA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
2. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
3. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
4. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
5. Arizonas Newest Medical School Opens
6. Scotland-based Innova Partnerships Ltd. Opens Boston Office
7. RxAlly Opens Its Doors In Leesburg, Virginia
8. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
9. Marken Opens Branch Office In Seoul, South Korea
10. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
11. Synchrogenix Opens in Sweden
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):